Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Annals of Oncology 26.6 (2015): S. 1238-1244.
- Schlagwort
-
-
Krebs
Onkologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Erlangen
- (wer)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (wann)
-
2016
- Urheber
-
Hecht, M.
Zimmer, L.
Loquai, C.
Weishaupt, C.
Gutzmer, R.
Schuster, B.
Gleisner, S.
Schulze, B.
Goldinger, S. M.
Berking, C.
Forschner, A.
Clemens, P.
Grabenbauer, G.
Müller-Brenne, T.
Bauch, J.
Eich, H. T.
Grabbe, S.
Schadendorf, D.
Schuler, G.
Keikavoussi, P.
Semrau, S.
Fietkau, R.
Distel, L. V.
Heinzerling, L.
- URN
-
urn:nbn:de:bvb:29-opus4-74937
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:54 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hecht, M.
- Zimmer, L.
- Loquai, C.
- Weishaupt, C.
- Gutzmer, R.
- Schuster, B.
- Gleisner, S.
- Schulze, B.
- Goldinger, S. M.
- Berking, C.
- Forschner, A.
- Clemens, P.
- Grabenbauer, G.
- Müller-Brenne, T.
- Bauch, J.
- Eich, H. T.
- Grabbe, S.
- Schadendorf, D.
- Schuler, G.
- Keikavoussi, P.
- Semrau, S.
- Fietkau, R.
- Distel, L. V.
- Heinzerling, L.
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Entstanden
- 2016
Ähnliche Objekte (12)
Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
Autocrine and paracrine effects of BRAF inhibitor induced senescence in melanoma
Characterization of the impact of BRAF-targeted inhibition in the melanoma microenvironment
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : : a retrospective multicenter study
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Braf, Albin
HuRdling Senescence: HuR Breaks BRAF-Induced Senescence in Melanocytes and Supports Melanoma Growth
Midkine in uveal melanoma: expression, mechanism and clinical relevance
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
Autocrine and paracrine effects of BRAF inhibitor induced senescence in melanoma
Characterization of the impact of BRAF-targeted inhibition in the melanoma microenvironment
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : : a retrospective multicenter study
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Braf, Albin
HuRdling Senescence: HuR Breaks BRAF-Induced Senescence in Melanocytes and Supports Melanoma Growth
Midkine in uveal melanoma: expression, mechanism and clinical relevance
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
Autocrine and paracrine effects of BRAF inhibitor induced senescence in melanoma
Characterization of the impact of BRAF-targeted inhibition in the melanoma microenvironment
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : : a retrospective multicenter study
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Braf, Albin
HuRdling Senescence: HuR Breaks BRAF-Induced Senescence in Melanocytes and Supports Melanoma Growth
Midkine in uveal melanoma: expression, mechanism and clinical relevance